Carbapenems: Difference between revisions
(Created page with "* Imipenem (+ cilastatin), meropenem ** Cephalosporin-resistant nosocomial bacteria ** Empirical treatment of serious infections in patients who recently received other b-lact...") |
Elcatracho (talk | contribs) |
||
| (6 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
==Types== | |||
#[[Ertapenem]] | |||
#[[Doripenem]] | |||
#[[Imipenem]] | |||
#[[Meropenem]] | |||
#[[Meropenem-vaborbactam]]<br /> | |||
==Indications== | |||
*Cephalosporin-resistant nosocomial bacteria | |||
*Empirical treatment of serious infections in patients who recently received other beta-lactams | |||
{{Template:Clinically Utilized Antibiotics}} | {{Template:Clinically Utilized Antibiotics}} | ||
| Line 7: | Line 14: | ||
==See Also== | ==See Also== | ||
*[[Antibiotics (Main)]] | *[[Antibiotics (Main)]] | ||
*[[Beta Lactams]] | |||
*[[Cephalosporin Cross-reactivity]] | |||
== | ==References== | ||
<references/> | |||
Goodman & Gilman's Pharmacology | Goodman & Gilman's Pharmacology | ||
[[Category: | [[Category:Pharmacology]] | ||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 05:14, 4 January 2022
Types
Indications
- Cephalosporin-resistant nosocomial bacteria
- Empirical treatment of serious infections in patients who recently received other beta-lactams
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
See Also
References
Goodman & Gilman's Pharmacology